Oxacillin Pediatric Dose — Bacterial Infections
Oxacillin is a penicillinase-resistant, semisynthetic penicillin that exerts its bactericidal effect by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins. It is active against methicillin-susceptible Staphylococcus aureus (MSSA) and streptococcal species, making it a first-line agent for serious MSSA infections in the pediatric population, including bacteremia, osteomyelitis, septic arthritis, and skin and soft tissue infections requiring parenteral therapy.
Pediatric Dosing
- Dose: 50 mg/kg/dose IV every 6 hours
- Adult dose: 2 g IV every 6 hours
Doses are administered intravenously at regular 6-hour intervals. Consult institutional protocol for weight-based maximum single-dose capping and duration of therapy based on the specific infection site.
Worked example: For a 20 kg child: 20 × 50 mg/kg = 1,000 mg (1 g) per dose, administered IV every 6 hours.
Indications and Clinical Context
Oxacillin is indicated for the treatment of infections caused by susceptible MSSA organisms. Common pediatric indications include bacteremia, infective endocarditis, osteomyelitis, septic arthritis, pneumonia, and complicated skin and soft tissue infections. It is the preferred beta-lactam over vancomycin when MSSA susceptibility is confirmed, given superior outcomes and a favorable safety profile for MSSA infections.
In the setting of empiric therapy where MRSA has not been excluded, local antibiogram data and institutional guidelines should guide initial agent selection. Once susceptibility to oxacillin is confirmed, de-escalation from broader agents (e.g., vancomycin) is strongly recommended per antimicrobial stewardship principles.
Administration and Monitoring
Oxacillin is administered exclusively via the intravenous route at this dosing regimen. Each dose is typically infused over 15–30 minutes. Intramuscular administration may be described in other contexts, but the source dosing pertains to IV delivery. Consult institutional protocol regarding compatibility, infusion concentration limits, and central versus peripheral line requirements for prolonged courses.
- Monitor: Hepatotoxicity (transaminase elevation is a known class effect; monitor LFTs with prolonged use), hypersensitivity reactions, and signs of superinfection.
- Contraindications: Known hypersensitivity to penicillins; use with caution in patients with a history of cephalosporin allergy (cross-reactivity is low but possible).
- Renal/hepatic adjustment: Consult institutional protocol for dose modifications in the setting of significant hepatic impairment.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.